Skip to main content

Key Product Details

Species Reactivity

Human

Applications

Blockade of Receptor-ligand Interaction

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG2A Clone # 528912

Product Specifications

Immunogen

Mouse myeloma cell line NS0-derived human VSIG4
Arg20-Pro283
Accession # Q9Y279

Specificity

Detects human VSIG4 in direct ELISAs.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG2A

Scientific Data Images for Human VSIG4 Antibody

Siglec-7 protein binding to VSIG4-transfected Human Cell Line is Blocked by VSIG4 Antibody. In a functional flow cytometry test.

Recombinant Human Siglec-7/Fc protein (1138-SL) binds to HEK293 human embryonic kidney cell line transfected with recombinant human VSIG4 and eGFP. (A) Binding is completely blocked by 50 µg/mL of Mouse Anti-Human VSIG4 Monoclonal Antibody (Catalog # MAB46462) but not by (B) Mouse IgG2A Isotype Control (MAB003). Protein binding was detected with Mouse Anti-Human IgG Fc APC-conjugated Monoclonal Antibody (FAB110A). Staining was performed using our Staining Membrane-Associated Proteins protocol.
Detection of Human VSIG4 by Immunocytochemistry/ Immunofluorescence

Detection of Human VSIG4 by Immunocytochemistry/ Immunofluorescence

VSIG4 blockade impairs C3b induced macrophages polarization. A Uniform manifold approximation and projection (UMAP) of single-cell RNA-seq from human decidual immune cells isolated from patients with RSA and healthy controls. The single-cell RNA sequencing data used in this study were previously published by Guo [9]. B Feature plot showed ICAM1 and VSIG4 expression in the different clusters between Ctrl vs. RSA as defined in (A). C Gene expression levels of VSIG4 and ICAM1 in decidual macrophages from normal pregnancies and RSA patients. D CLSM images showing the expression of VSIG4 protein in decidual macrophages from normal pregnancies and RSA patients. Scale bars = 5 μm. E Statistical histogram of VSIG4 mean fluorescence intensity of each decidual macrophages from normal pregnancies (n = 3) and RSA patients (n = 3). F Gene expression levels of IL1B, IL6 and TNF in macrophages with or without the addition of VSIG4 blocking antibody during co-culture with dNK. G Representative mean fluorescence intensity of CD80 (upper panel) or CD206 (lower panel) in macrophages with or without the addition of VSIG4 blocking antibody during co-culture with dNK. Experiments were repeated for 3 independent times. P values have been determined by two-tailed paired t-test Image collected and cropped by CiteAb from the following open publication (https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-024-05829-w), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human VSIG4 by Immunocytochemistry/ Immunofluorescence

Detection of Human VSIG4 by Immunocytochemistry/ Immunofluorescence

dNK cells from normal pregnancy express the natural ligand of VSIG4. A Gene expression levels of VSIG4 in peripheral blood NK cells (pNK), peripheral blood monocytes (pM), decidual macrophages (dM), and decidual NK cells (dNK). B Fluorescence image depicting the expression of VSIG4 protein on decidual macrophages. C Biological processes that are significantly enriched in Sankey dot pathway enrichment analysis of the upregulated genes of dNK relative to pNK. D Heat map of differential genes in complement and coagulation cascade pathways, n = 3 per group. E Gene set enrichment analysis (GSEA) revealed an increase in complement and coagulation cascade pathways (enrichment plot: COMPLEMENT AND COAGULATION CASCADES PATHWAYS, HSA04610) in dNK cells compared with pNK cells, n = 3 per group. F qPCR validation of the differential expression of the C3 gene in dNK cells and pNK cells. G CLSM images showing the secretion of C3b in pNKs and dNKs. The images were captured using the same parameters. Scale bars = 5 μm. H Statistical histogram of C3b mean fluorescence intensity of each decidual or peripheral NK cell. P values have been determined by two-tailed unpaired t-test Image collected and cropped by CiteAb from the following open publication (https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-024-05829-w), licensed under a CC-BY license. Not internally tested by R&D Systems.

Applications for Human VSIG4 Antibody

Application
Recommended Usage

Blockade of Receptor-ligand Interaction

50 µg/mL
Sample: In a functional flow cytometry test, 50 μg/mL of Mouse Anti-Human VSIG4 Antibody(Catalog # MAB46462) will block the binding of Recombinant Human Siglec-7/Fc protein (Catalog # 1138-SL) to HEK293 human embryonic kidney cell line transfected with recombinant human VSIG4.

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: VSIG4

VSIG4 (Vset and immunoglobulin domain containing 4), also known as complement receptor immunoglobulin (CRIg) and Z39IG, is a 45 kDa, type I transmembrane protein of the B7 family within the Ig superfamily that is expressed only in tissue resident macrophages (1-4). The gene is located on the X chromosome (2). The human VSIG4 cDNA encodes 399 amino acids (aa) including a 19 aa signal sequence, a 264 aa extracellular domain (ECD) containing a V-type and a C2-type Ig domain, a 21 aa transmembrane domain and a 95 aa cytoplasmic domain (3). The human VSIG4 ECD shares 84% aa identity with canine VSIG4. Within the IgV domain, it shares 90%, 80% and 78% aa identity with bovine, mouse and rat VSIG4, respectively; these animals lack the C2-type domain. Splice isoforms of 321, 305, 272, 201 and 199 aa lack all or part of the cytoplasmic domain, the C2-type Ig domain and/or the transmembrane domain (5). VSIG4 is specifically expressed on macrophages in the thymic medulla, peritoneum, alveoli, synovia, adipose and heart, liver Kupffer cells, placental Hofbauer cells, and atherosclerotic foam cells (1-4, 6-9). It is absent on infiltrating macrophages (8). VSIG4 is a complement receptor that binds C3b and iC3b fragments, internalizes them to recycling endosomes, and is recycled to the cell surface (4, 6). It contributes significantly to innate immunity by binding and phagocytosis of complement opsonized invading pathogens (4, 8, 10). Binding of either native or recombinant soluble VSIG4 to C3b inhibits complement amplification through the alternative, but not classical, pathway (10, 11). VSIG4 is also a negative regulator of mouse and human T cell activation (2). Although VSIG4 engagement may activate NF kappaB and thus be proinflammatory in some cases, many of its activities are important in resolving, rather than initiating, inflammation (1, 2, 7, 10, 11). There is emerging evidence in human conditions that VSIG4 may be a valuable biomarker in infection and immunity, inflammatory conditions and cancer prognosis (12, 13, 14).

References

  1. He, J.Q. et al. (2008) Mol. Immunol. 4041.
  2. Vogt, L. et al. (2006) J. Clin. Invest. 116:2817.
  3. Langnaese, K. et al. (2000) Biochim. Biophys. Acta 1492:522.
  4. Helmy, K. et al. (2006) Cell 124:915.
  5. Entrez protein Accession # EAX05393, NP_001093901, CAI42052, CAI4205, EAX05394.
  6. Tanaka, M. et al. (2008) Clin. Exp. Immunol. 154:38.
  7. Lee, M.Y. et al. (2006) J. Leukoc. Biol. 80:922.
  8. Gorgani, N.N. et al. (2008) J. Immunol. 181:7902.
  9. Walker, M.G. (2002) Biochim. Biophys. Acta 1574:387.
  10. Wiesmann, C. et al. (2006) Nature 444:217.
  11. Katschke, K.J. et al. (2007) J. Exp. Med. 204:1319.
  12. Small, A.G. et al. (2016) Swiss Med Wkly. 5:146.
  13. Roh J. et al. (2017) Oncotarget. 8:58122.
  14. Kim K.H. et al. (2016) Autophagy. 12:1647.

Long Name

V-Set and Immunoglobulin Domain Containing 4

Alternate Names

Z39IG

Entrez Gene IDs

11326 (Human); 278180 (Mouse); 312102 (Rat); 102144784 (Cynomolgus Monkey)

Gene Symbol

VSIG4

UniProt

Additional VSIG4 Products

Product Documents for Human VSIG4 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Human VSIG4 Antibody

For research use only

Loading...
Loading...
Loading...